Pi Therapeutics
Inhibitors for Cancer Treatment
Company Overview
Snapshot
Founded in March 2015 by Ori Kalid, Pi Therapeutics operated with 1–10 employees. The company raised capital across two funding rounds from 11 investors, with Pontifax participating as a lead investor in one of its rounds. In April 2023, the company ceased operations.
Business overview
Pi Therapeutics was a preclinical-stage pharmaceutical company focused on developing protein degradation modulators for cancer treatment. Its core technology involved a lead drug that modulated pathways related to proteostasis, designed to preferentially target cancer cells. The company aimed to address both hematologic and solid tumor indications within the biopharmaceutical and pharma sectors, with its technology in-licensed from Johns Hopkins University.
Strategic signal
Pi Therapeutics ceased operations in April 2023. This indicates a significant shift in the company's trajectory, signaling to investors that its preclinical development efforts did not lead to a sustainable business model or further investment, despite earlier funding rounds.
Log in to access full profile ›Company Intelligence Q&A
- What was the primary focus of Pi Therapeutics?
- Pi Therapeutics focused on the development of protein degradation modulators for the treatment of cancer, utilizing a unique approach to target cancer cells preferentially.
- When did Pi Therapeutics cease operations?
- Pi Therapeutics ceased to operate in April 2023.
- Who was a key founder of Pi Therapeutics?
- Ori Kalid was a co-founder and CEO of Pi Therapeutics.
- Which investors participated in Pi Therapeutics' Series B funding round?
- In May 2019, Pi Therapeutics secured a Series B funding round with participation from Pontifax.
- From where did Pi Therapeutics license its core technology?
- Pi Therapeutics was founded based on technology in-licensed from Johns Hopkins University.